Clinical Trial

Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease

Study acronym: A3D
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A3D is a phase I/II clinical trial. The primary objective is to evaluate the safety of allogeneic adipose tissue derived-stem cells (AdMSC) administered by intravenous (IV) route in mild to moderate Alzheimer disease (AD) using a dose escalation protocol.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-06-24
notable Primary completion pushed: 2029-03-01 -> 2029-05-01 2026-06-24
minor Completion pushed: 2029-03-01 -> 2029-05-01 2026-06-24
Trial Details
NCT Number NCT07367815
Lead Sponsor University Hospital, Toulouse
Conditions Alzheimer Disease
Enrollment 9 participants
Start Date 2026-05-07
Primary Completion 2029-05-01 (estimated)
Study Completion 2029-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-23